ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
1541
Classifica tra le azioni
#19248
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Prezzo delle azioni
$0.38122017
Ultima sincronizzazione: 2026-10-16
Capitalizzazione di mercato
$159.74M
Variazione (1 giorno)
2.58%
Variazione (1 anno)
-71.65%
Paese
CN
Scambia ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
Categoria
Healthcare
Capitalizzazione di mercato di ImmuneOnco Biopharmaceuticals (Shanghai) Inc.(1541)
Capitalizzazione di mercato: $159.74M
A partire dal October 2026, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ha una capitalizzazione di mercato pari a $159.74M. Questo rende ImmuneOnco Biopharmaceuticals (Shanghai) Inc. la 19248th azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di ImmuneOnco Biopharmaceuticals (Shanghai) Inc. dal 2023 al 2026
1541 in paragone con la classifica dei più popolari stocks
| Il prezzo per 1541 | Attivo B | Capitalizzazione del mercato a B | Risultati | |
|---|---|---|---|---|
$12,534.39
$159.74M
|
$5.252T | +3,287,865.92% | ||
|
$11,935.22
$159.74M
|
$5.001T | +3,130,693.68% | ||
|
$9,966.12
$159.74M
|
$4.176T | +2,614,167.56% | ||
|
$9,469.52
$159.74M
|
$3.968T | +2,483,903.14% | ||
|
$6,770.56
$159.74M
|
$2.837T | +1,775,923.15% |
